Since the pivotal Strategic timing of the antiretroviral treatment trial, the timing of therapy has drastically altered and is now advocated at the time of diagnosis irrespective of baseline CD4 count and may even be provided the same day, minimizing potential harms and immune dysfunction from delaying treatment until quantitative immune cell deficits have been detected providing a near normal life expectancy.11 The gene discussed is CD4; the disease is immune system disorder.